NESBID: Neuro-Stimulation of the Brain in Depression

Status Active, not recruiting

Clinical Trial Summary

In Canada, approximately 20% of patients with Major Depressive Disorder (MDD) have treatment-resistance and fail to respond to trials of pharmacotherapy or psychotherapy. Although the treatment of choice has historically consisted of electroconvulsive therapy (ECT), this is not always feasible or practical, and carries a risk of side-effects that may be unacceptable to certain patients. In this pragmatic, multi-site, placebo-controlled and double-blinded clinical trial, participants with ultra treatment-resistant MDD will be randomized to receive either active or sham transcranial direct current stimulation in addition to their usual treatment. Ultra treatment-resistant depression will be operationally defined as MDD that has failed to respond to at least five previous trials of antidepressants at sufficient doses, or ECT, or ketamine. Patients will receive a total of 30 active or sham treatment sessions (5 per week), for 30 minutes per session. In both groups, the anode will be placed over the left dorsolateral prefrontal cortex (position F3), and the cathode over the right dorsolateral prefrontal cortex (position F4). Patients in the sham group will receive electrical stimulation at 2 mA for less than 30 seconds, whereas patients in the active group will receive that level of stimulation for the entire duration of treatment. The study's primary outcome is the change in score on a clinician-graded depression inventory (the Montgomery-Asberg Depression Rating Scales). Secondary outcomes include change in scores on a self-administered depression rating scale and measurement of function scale. Information on language ability will also be collected, as will data on side-effects of treatment. Scores will be collected before the trial start, after every 10 sessions, and one month after trial completion.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Depression
Depressive Disorder
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
Electric Stimulation Therapy
Transcranial Direct Current Stimulation

Clinical Trial Details

NCT number	NCT04159012
Study type	Interventional
Source	University of Alberta
Contact
Status	Active, not recruiting
Phase	N/A
Start date	September 1, 2020
Completion date	December 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05915013` - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	Phase 1
Completed	`NCT04469322` - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression	N/A
Recruiting	`NCT05415397` - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs	Phase 3
Recruiting	`NCT05988333` - Psychoeducational Intervention for Families With a Member Affected by Major Depression	N/A
Completed	`NCT02919501` - Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder	Phase 2
Completed	`NCT00976560` - Clinical Study to Test a New Drug to Treat Major Depression	Phase 2
Recruiting	`NCT05518149` - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)	Phase 3
Not yet recruiting	`NCT06303076` - Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial	Phase 4
Not yet recruiting	`NCT05901571` - Acupuncture and Escitalopram for Treating Major Depression Clinical Study	N/A
Suspended	`NCT02546024` - Predictors of Treatment Response in Late-onset Major Depressive Disorder	N/A
Completed	`NCT02452892` - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)	N/A
Completed	`NCT01407575` - Buprenorphine for Treatment Resistant Depression	Phase 3
Completed	`NCT01583400` - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial	N/A
Completed	`NCT01152996` - Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study	Phase 3
Enrolling by invitation	`NCT00762866` - Psychiatric Genotype/Phenotype Project Repository
Completed	`NCT00384033` - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder	Phase 3
Completed	`NCT00369343` - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women	Phase 3
Completed	`NCT00366652` - Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects	Phase 3
Completed	`NCT00316160` - Sexual Functioning Study With Antidepressants	Phase 4
Completed	`NCT00149643` - Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NESBID: Neuro-Stimulation of the Brain in Depression — NESBID

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms